Jiangsu Changfeng Pharmaceutical

Changfeng Pharmaceutical is a China-based biopharmaceutical company specializing in the development and commercialization of inhalation products for respiratory diseases. The company focuses on high-entry-barrier drug delivery technologies, including metered-dose inhalers (MDI), dry powder inhalers (DPI), nebulizers, and nasal sprays. Its portfolio targets major respiratory conditions such as asthma, COPD, and allergic rhinitis, with several products already approved or in late-stage clinical trials. Changfeng aims to provide high-quality, affordable respiratory medicines for both the Chinese and global markets by integrating R&D with large-scale GMP manufacturing.